Latest Insider Transactions at Bolt Biotherapeutics, Inc. (BOLT)
This section provides a real-time view of insider transactions for Bolt Biotherapeutics, Inc. (BOLT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Bolt Biotherapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Bolt Biotherapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2023
|
William P. Quinn President, CEO and CFO |
BUY
Open market or private purchase
|
Direct |
7,500
+17.13%
|
$0
$0.95 P/Share
|
|
Dec 06
2023
|
William P. Quinn President, CEO and CFO |
BUY
Open market or private purchase
|
Direct |
2,500
+7.99%
|
$0
$0.78 P/Share
|
|
Nov 30
2023
|
Edgar Engleman Director |
SELL
Open market or private sale
|
Indirect |
123,079
-5.6%
|
$0
$0.86 P/Share
|
|
Nov 29
2023
|
Edgar Engleman Director |
SELL
Open market or private sale
|
Indirect |
25,805
-1.16%
|
$0
$0.91 P/Share
|
|
Nov 21
2023
|
Edgar Engleman Director |
SELL
Open market or private sale
|
Indirect |
1,943
-0.09%
|
$0
$0.9 P/Share
|
|
Nov 21
2023
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,400
-0.49%
|
$0
$0.9 P/Share
|
|
Nov 20
2023
|
Edgar Engleman Director |
SELL
Open market or private sale
|
Indirect |
31,257
-1.39%
|
$0
$0.92 P/Share
|
|
Nov 20
2023
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
54,700
-6.65%
|
$0
$0.92 P/Share
|
|
Nov 17
2023
|
Edgar Engleman Director |
SELL
Open market or private sale
|
Indirect |
9,345
-0.41%
|
$0
$0.93 P/Share
|
|
Nov 17
2023
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,143
-2.65%
|
$0
$0.93 P/Share
|
|
Nov 17
2023
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,211
-0.41%
|
$0
$0.93 P/Share
|
|
Nov 16
2023
|
Edgar Engleman Director |
SELL
Open market or private sale
|
Indirect |
8,571
-0.38%
|
$0
$0.96 P/Share
|
|
Nov 16
2023
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,000
-1.68%
|
$0
$0.96 P/Share
|
|
Jun 06
2023
|
William P. Quinn President, CEO and CFO |
BUY
Open market or private purchase
|
Direct |
1,829
+6.51%
|
$1,829
$1.18 P/Share
|
|
Jul 13
2022
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
800,000
-17.76%
|
$1,600,000
$2.0 P/Share
|
|
Dec 22
2021
|
Edith A. Perez Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,714
+49.09%
|
$71,428
$2.8 P/Share
|
|
Dec 08
2021
|
William P. Quinn President, CEO and CFO |
BUY
Open market or private purchase
|
Direct |
5,000
+19.88%
|
$20,000
$4.71 P/Share
|
|
Dec 06
2021
|
Edith A. Perez Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
411
+23.63%
|
$1,644
$4.64 P/Share
|
|
Dec 06
2021
|
William P. Quinn President, CEO and CFO |
BUY
Open market or private purchase
|
Direct |
35
+0.23%
|
$140
$4.64 P/Share
|
|
Jun 04
2021
|
Edith A. Perez Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
917
+50.0%
|
$14,672
$16.65 P/Share
|
|
Jun 04
2021
|
William P. Quinn President, CEO and CFO |
BUY
Open market or private purchase
|
Direct |
1,221
+7.47%
|
$19,536
$16.65 P/Share
|
|
Feb 09
2021
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
400,000
+8.16%
|
$8,000,000
$20.0 P/Share
|
|
Feb 09
2021
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,027,088
+49.53%
|
-
|
|
Feb 09
2021
|
Randall C Schatzman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,500
+50.0%
|
$30,000
$20.0 P/Share
|
|
Feb 09
2021
|
William P. Quinn President, CEO and CFO |
BUY
Open market or private purchase
|
Direct |
1,200
+7.95%
|
$24,000
$20.0 P/Share
|
|
Feb 09
2021
|
Edgar Engleman Director |
BUY
Open market or private purchase
|
Indirect |
200,000
+8.09%
|
$4,000,000
$20.0 P/Share
|
|
Feb 09
2021
|
Edgar Engleman Director |
SELL
Open market or private sale
|
Indirect |
164
-0.01%
|
$3,280
$20.0 P/Share
|
|
Feb 09
2021
|
Edgar Engleman Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
46,608
+2.2%
|
$0
$0.07 P/Share
|
|
Feb 09
2021
|
Edgar Engleman Director |
BUY
Conversion of derivative security
|
Indirect |
1,997,991
+27.94%
|
-
|
|
Feb 09
2021
|
Ashish Siri Ram Khanna Director |
BUY
Open market or private purchase
|
Indirect |
1,200
+50.0%
|
$24,000
$20.0 P/Share
|
|
Feb 09
2021
|
Ashish Siri Ram Khanna Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$20,000
$20.0 P/Share
|
|
Feb 09
2021
|
James Healy |
BUY
Open market or private purchase
|
Indirect |
450,000
+14.04%
|
$9,000,000
$20.0 P/Share
|
|
Feb 09
2021
|
James Healy |
BUY
Conversion of derivative security
|
Indirect |
2,304,437
+42.12%
|
-
|
|
Feb 09
2021
|
Mahendra Shah |
SELL
Open market or private sale
|
Indirect |
62
-0.0%
|
$1,240
$20.0 P/Share
|
|
Feb 09
2021
|
Mahendra Shah |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
17,711
+1.21%
|
$0
$0.07 P/Share
|
|
Feb 09
2021
|
Mahendra Shah |
BUY
Conversion of derivative security
|
Indirect |
1,416,352
+37.22%
|
-
|
|
Feb 09
2021
|
Kathleen Laporte |
BUY
Open market or private purchase
|
Direct |
1,200
+50.0%
|
$24,000
$20.0 P/Share
|
|
Feb 09
2021
|
Vivo Capital Viii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
350,000
+22.06%
|
$7,000,000
$20.0 P/Share
|
|
Feb 09
2021
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
226
-0.01%
|
$4,520
$20.0 P/Share
|
|
Feb 09
2021
|
Vivo Capital Viii, LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
64,319
+1.87%
|
$0
$0.07 P/Share
|
|
Feb 09
2021
|
Vivo Capital Viii, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,414,343
+30.26%
|
-
|
|
Feb 09
2021
|
Sofinnova Venture Partners X, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
450,000
+14.04%
|
$9,000,000
$20.0 P/Share
|
|
Feb 09
2021
|
Sofinnova Venture Partners X, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,304,437
+42.12%
|
-
|